Pharmacy leaders flock to Capitol for second NACDS RxIMPACT Day
WASHINGTON The National Association of Chain Drug Stores and its members are staging a two-day, full-court press on Capitol Hill Wednesday and Thursday as they take their case for pharmacy’s critical role in a revamped healthcare system directly to Congress.
The Second Annual NACDS RxIMPACT Day has brought 250 pharmacy leaders to the nation’s capitol for an intense lobbying effort with members of Congress. The goal, noted NACDS: to deliver “a powerful message about the link between pharmacy services and the cost savings and health improvements that result when patients take their medications as prescribed.”
A dramatic jump in the number of attendees has fueled momentum for the event. The number of attendees representing community pharmacy is up 67% from last year, NACDS reports, with a 33% increase in the number of states represented [36, compared with 27 states in 2009]. A total of 25 state pharmacy associations are also represented at this year’s RxIMPACT Day, compared with 10 last year and the number of pharmacy school representatives descending on Capitol Hill has grown from just two in 2009 to 16 this year.
“Last year, NACDS made a strong statement with this event that pharmacy is committed to telling its story as the face of neighborhood health care, and that pharmacy is determined to do what it takes to deserve victories in the public policy arena,” said NACDS president and CEO Steve Anderson. “The success stories of those who pioneered the event in 2009, combined with additional victories for the NACDS pro-patient, pro-pharmacy agenda, have generated tremendous enthusiasm for this program in 2010.”
Participants in the event are reminding congressional representatives of “pharmacy’s ability to help reduce the estimated $290 billion in annual costs that result from failure to take medications as prescribed,” according to the organization. Pharmacy advocates are urging also lawmakers to support policies that advance and standardize pharmacists’ delivery of medication therapy management services to patients – and establish compensation standards for those services.
Also on the lobbying wish list: a legislative remedy to the Medicaid average manufacturer price [AMP] model for prescription payments, which pharmacists have long argued would force some pharmacies out of business or at least out of the business of serving Medicaid patients, thus jeopardizing patients’ access to pharmacies. Pharmacy representatives also are urging lawmakers to overturn policies and proposals that stymie their ability to sell vaccines and durable medical equipment such as diabetes testing supplies at neighborhood pharmacies.
The RxIMPACT event concludes March 11. In addition to the efforts of those participating in person, NACDS is conducting a “Virtual Hill Day” through which pharmacy advocates are contacting their elected officials via e-mail and mail.
No comments found
RediClinic offering Latisse consultations
HOUSTON RediClinic, which operates 22 retail health clinics inside select H-E-B stores in the Greater Houston and Austin area, now is offering Latisse, an FDA-approved prescription treatment to grow lashes.
Latisse is a prescription treatment for hypotrichosis used to grow eyelashes. Eyelash hypotrichosis is another name for not having enough eyelashes or eyelashes that are inadequate. The topical solution must be applied each night on the skin of the upper eyelid margins at the base of the eyelashes. Results are gradual and peak after 12 to 16 weeks.
RediClinic is offering Latisse consultations for $69.
Good to know this. Many women would love to consult first before jumping to using Latisse or buy latisse. It is always good to know first if you are okay with anything you are going to take.
Where exactly can I find this clinic? I want to consult in a very prestigious clinic first before I will purchase and use Latisse. Just want to make sure. Shay Arrellin buy latisse
Bristol-Myers Squibb, AstraZeneca announce postmarketing study for Onglyza
WILMINGTON, Del. Two drug makers hope to find out how well a diabetes drug works in treating patients who run the risk of developing cardiovascular diseases in a post-marketing study announced Tuesday.
Bristol-Myers Squibb and AstraZeneca announced the start of a phase 4 study of 12,000 patients with Type 2 diabetes treated with the drug Onglyza (saxagliptin). The placebo-controlled study, called SAVOR-TIMI 53, will take place over a five-year period and follow patients who have a history of previous cardiovascular problems or multiple risk factors for vascular disease, with the goal of determining whether adding Onglyza to their current standard of care will reduce their risk of cardiovascular death, heart attack or stroke.
The Food and Drug Administration approved Onglyza in July 2009.
No comments found